124 related articles for article (PubMed ID: 34674001)
21. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
22. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
[TBL] [Abstract][Full Text] [Related]
23. Comparison of paclitaxel-coated balloon angioplasty with femoropopliteal bypass surgery in treating femoropopliteal lesions.
Kavala AA; Kuserli Y; Turkyilmaz S
Vascular; 2021 Apr; 29(2):260-269. PubMed ID: 32838692
[TBL] [Abstract][Full Text] [Related]
24. Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial.
Teichgräber U; Ingwersen M; Platzer S; Lehmann T; Zeller T; Aschenbach R; Scheinert D
Trials; 2021 Sep; 22(1):665. PubMed ID: 34583746
[TBL] [Abstract][Full Text] [Related]
25. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Common Femoral Artery Atherosclerotic Disease.
Stavroulakis K; Schwindt A; Torsello G; Beropoulis E; Stachmann A; Hericks C; Bollenberg L; Bisdas T
J Endovasc Ther; 2018 Feb; 25(1):92-99. PubMed ID: 29251204
[TBL] [Abstract][Full Text] [Related]
26. Treatment of femoropopliteal atherosclerotic lesions using the ranger paclitaxel-coated balloon catheter: 12-month results from an all-comers registry.
Lichtenberg M; von Bilderling P; Ranft J; Niemöller K; Grell H; Briner L; Saucy F; Rassaf T; Breuckmann F
J Cardiovasc Surg (Torino); 2018 Feb; 59(1):45-50. PubMed ID: 28980462
[TBL] [Abstract][Full Text] [Related]
27. Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Giacoppo D; Cassese S; Harada Y; Colleran R; Michel J; Fusaro M; Kastrati A; Byrne RA
JACC Cardiovasc Interv; 2016 Aug; 9(16):1731-42. PubMed ID: 27539695
[TBL] [Abstract][Full Text] [Related]
28. Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The VIVA REALITY study.
Rocha-Singh KJ; Sachar R; DeRubertis BG; Nolte-Ernsting CCA; Winscott JG; Krishnan P; Scott EC; Garcia LA; Baeriswyl JL; Ansel G; Rosenfield K; Zeller T;
Catheter Cardiovasc Interv; 2021 Sep; 98(3):549-558. PubMed ID: 34080792
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
[No Abstract] [Full Text] [Related]
30. Mid-term outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of femoropopliteal disease.
Foley TR; Cotter RP; Kokkinidis DG; Nguyen DD; Waldo SW; Armstrong EJ
Catheter Cardiovasc Interv; 2017 May; 89(6):1078-1085. PubMed ID: 28295971
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial.
Salisbury AC; Li H; Vilain KR; Jaff MR; Schneider PA; Laird JR; Cohen DJ
JACC Cardiovasc Interv; 2016 Nov; 9(22):2343-2352. PubMed ID: 27884360
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: A single center experience (JET-SCE).
Shammas NW; Shammas GA; Jones-Miller S; Shammas WJ; Bou-Dargham B; Shammas AN; Banerjee S; Rachwan RJ; Daher GE
Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):771-777. PubMed ID: 30420096
[TBL] [Abstract][Full Text] [Related]
33. Photoablative atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis in instent femoro-popliteal obstructions (PHOTOPAC).
Böhme T; Noory E; Beschorner U; Lerke F; Schmidt A; Scheinert D; Ito W; Zeller T; Rastan A
Vasa; 2021 Sep; 50(5):387-393. PubMed ID: 34107772
[No Abstract] [Full Text] [Related]
34. Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis.
Cassese S; Wolf F; Ingwersen M; Kinstner CM; Fusaro M; Ndrepepa G; Ibrahim T; Ott I; Lammer J; Krankenberg H; Fusaro M
Circ Cardiovasc Interv; 2018 Dec; 11(12):e007055. PubMed ID: 30562083
[TBL] [Abstract][Full Text] [Related]
35. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
[TBL] [Abstract][Full Text] [Related]
36. Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I.
Xu Y; Jia X; Zhang J; Zhuang B; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
JACC Cardiovasc Interv; 2018 Dec; 11(23):2347-2353. PubMed ID: 30448170
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in patients with ulcerations and gangrene - a single center experience.
Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Kuhn LM; Nührenberg T; Neumann FJ; Zeller T
Vasa; 2021 Feb; 50(2):132-138. PubMed ID: 33118425
[No Abstract] [Full Text] [Related]
38. Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis.
Gurin MI; Beyer SE; Weinberg M; Parikh SA; Armstrong EJ; Albaghdadi MS; Aronow HD; Carroll BJ; Yeh R; Secemsky EA
J Endovasc Ther; 2021 Apr; 28(2):246-254. PubMed ID: 33426984
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of adjunctive drug-coated balloon therapy in endovascular treatment of common femoral artery disease.
Imran HM; Hyder ON; Soukas PA
Cardiovasc Revasc Med; 2019 Mar; 20(3):210-214. PubMed ID: 29970328
[TBL] [Abstract][Full Text] [Related]
40. Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions.
Zeller T; Brechtel K; Meyer DR; Noory E; Beschorner U; Albrecht T
J Endovasc Ther; 2020 Oct; 27(5):683-690. PubMed ID: 32666871
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
